[
  {
    "ts": null,
    "headline": "Top Analyst Reports for NVIDIA, Cisco & Linde",
    "summary": "NVIDIA, Cisco and Linde post strong gains as analysts spotlight AI growth, software expansion and industrial gas leadership.",
    "url": "https://finnhub.io/api/news?id=5dcf821d2d30593fc2820d7594b618c843f9f1451727b984ebba7988f801c1c4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755894420,
      "headline": "Top Analyst Reports for NVIDIA, Cisco & Linde",
      "id": 136496075,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NVIDIA, Cisco and Linde post strong gains as analysts spotlight AI growth, software expansion and industrial gas leadership.",
      "url": "https://finnhub.io/api/news?id=5dcf821d2d30593fc2820d7594b618c843f9f1451727b984ebba7988f801c1c4"
    }
  },
  {
    "ts": null,
    "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of August 24",
    "summary": "Dividend Champion, Contender, And Challenger Highlights: Week Of August 24",
    "url": "https://finnhub.io/api/news?id=f690af61c896f046b572e7a954d2d57a40b46fc083063ba8c71308e9bc4c5601",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755887292,
      "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of August 24",
      "id": 136485520,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=f690af61c896f046b572e7a954d2d57a40b46fc083063ba8c71308e9bc4c5601"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Pins Hopes on Rinvoq to Drive Next Phase of Growth",
    "summary": "ABBV posts strong phase III alopecia areata data from the second study on Rinvoq. The drug hit $3.7B in H1 sales and is expected to further drive growth in H2.",
    "url": "https://finnhub.io/api/news?id=70f3dd6c2b69b2c91a5bf2faf1f22e846bf3388610f0401f0532df8a98bdeb6d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755869940,
      "headline": "AbbVie Pins Hopes on Rinvoq to Drive Next Phase of Growth",
      "id": 136478895,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "ABBV posts strong phase III alopecia areata data from the second study on Rinvoq. The drug hit $3.7B in H1 sales and is expected to further drive growth in H2.",
      "url": "https://finnhub.io/api/news?id=70f3dd6c2b69b2c91a5bf2faf1f22e846bf3388610f0401f0532df8a98bdeb6d"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=6a1b98bbbedb7f1c944319ad49c2ce034e8cda2f7b905bfcb8382cc183244b36",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755867604,
      "headline": "Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know",
      "id": 136476811,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=6a1b98bbbedb7f1c944319ad49c2ce034e8cda2f7b905bfcb8382cc183244b36"
    }
  },
  {
    "ts": null,
    "headline": "ABBV's Improving Oncology Sales Poise It Well for Long-Term Growth",
    "summary": "AbbVie's oncology sales climbed 4.2% in H1 2025 as new drugs offset Imbruvica declines, strengthening its long-term growth outlook.",
    "url": "https://finnhub.io/api/news?id=a7b2ccc1f9ade8de00401e0212298710d33b7bd95149a5b22a9b9be9139c8f8d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755866580,
      "headline": "ABBV's Improving Oncology Sales Poise It Well for Long-Term Growth",
      "id": 136476664,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "AbbVie's oncology sales climbed 4.2% in H1 2025 as new drugs offset Imbruvica declines, strengthening its long-term growth outlook.",
      "url": "https://finnhub.io/api/news?id=a7b2ccc1f9ade8de00401e0212298710d33b7bd95149a5b22a9b9be9139c8f8d"
    }
  },
  {
    "ts": null,
    "headline": "Investors Crave Long-Term Debt, But Firms Don’t Want to Sell",
    "summary": "When blue-chip companies have sold debt maturing in 30 years or more in the US, they’ve found heavy demand, with money managers placing orders equal to about five times the notes for sale on average.  Drugmaker Eli Lilly & Co drew $14.7 billion of orders earlier this week for just $2 billion of 30- and 40-year bonds.  Investors are eager to lock in yields above 5.5%, a relatively high level, especially as money managers enjoy robust inflows and the Federal Reserve gets closer to cutting rates.",
    "url": "https://finnhub.io/api/news?id=5a68ebd2e1f002224dadbac608b50cb7f6df768e90c4de79fe70887b6e682f67",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755864009,
      "headline": "Investors Crave Long-Term Debt, But Firms Don’t Want to Sell",
      "id": 136476603,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "When blue-chip companies have sold debt maturing in 30 years or more in the US, they’ve found heavy demand, with money managers placing orders equal to about five times the notes for sale on average.  Drugmaker Eli Lilly & Co drew $14.7 billion of orders earlier this week for just $2 billion of 30- and 40-year bonds.  Investors are eager to lock in yields above 5.5%, a relatively high level, especially as money managers enjoy robust inflows and the Federal Reserve gets closer to cutting rates.",
      "url": "https://finnhub.io/api/news?id=5a68ebd2e1f002224dadbac608b50cb7f6df768e90c4de79fe70887b6e682f67"
    }
  },
  {
    "ts": null,
    "headline": "My 5 Favorite Stocks to Buy Right Now",
    "summary": "Not every ticker worth owning at this time has raced to an uncomfortably high price.",
    "url": "https://finnhub.io/api/news?id=67abe8fc633c4608f5fddde7dbc54f0c97affbfe0de3227b0d524131f22fc049",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755851700,
      "headline": "My 5 Favorite Stocks to Buy Right Now",
      "id": 136476732,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Not every ticker worth owning at this time has raced to an uncomfortably high price.",
      "url": "https://finnhub.io/api/news?id=67abe8fc633c4608f5fddde7dbc54f0c97affbfe0de3227b0d524131f22fc049"
    }
  }
]